Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Effects of Glutathione Transferase-Targeting Nitrobenzoxadiazole Compounds in Relation to PD-L1 Status in Human Melanoma Cells.

Sciarretta F, Fulci C, Palumbo C, Rotili D, Tentori L, Graziani G, Caccuri AM.

Chemotherapy. 2019 Oct 22:1-8. doi: 10.1159/000503339. [Epub ahead of print]

PMID:
31639786
2.

Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.

Faraoni I, Consalvo MI, Aloisio F, Fabiani E, Giansanti M, Di Cristino F, Falconi G, Tentori L, Di Veroli A, Curzi P, Maurillo L, Niscola P, Lo-Coco F, Graziani G, Voso MT.

Cancers (Basel). 2019 Sep 16;11(9). pii: E1373. doi: 10.3390/cancers11091373.

3.

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid.

Ceci C, Lacal PM, Tentori L, De Martino MG, Miano R, Graziani G.

Nutrients. 2018 Nov 14;10(11). pii: E1756. doi: 10.3390/nu10111756. Review.

4.

Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?

Franzese O, Battaini F, Graziani G, Tentori L, Barbaccia ML, Aquino A, Roselli M, Fuggetta MP, Bonmassar E, Torino F.

Pharmacol Res. 2018 May;131:1-6. doi: 10.1016/j.phrs.2018.03.005. Epub 2018 Mar 9. Review.

PMID:
29530602
5.

Poly(ADP-ribose) polymerase inhibitor olaparib hampers placental growth factor-driven activation of myelomonocytic cells.

Lacal PM, Atzori MG, Ruffini F, Tentori L, Graziani G.

Oncol Rep. 2018 May;39(5):2261-2269. doi: 10.3892/or.2018.6291. Epub 2018 Mar 5.

PMID:
29512738
6.

The Anti-Vascular Endothelial Growth Factor Receptor-1 Monoclonal Antibody D16F7 Inhibits Glioma Growth and Angiogenesis In Vivo.

Atzori MG, Tentori L, Ruffini F, Ceci C, Bonanno E, Scimeca M, Lacal PM, Graziani G.

J Pharmacol Exp Ther. 2018 Jan;364(1):77-86. doi: 10.1124/jpet.117.244434. Epub 2017 Oct 12.

PMID:
29025978
7.

Modulation of GDF11 expression and synaptic plasticity by age and training.

De Domenico E, D'Arcangelo G, Faraoni I, Palmieri M, Tancredi V, Graziani G, Grimaldi P, Tentori L.

Oncotarget. 2017 Aug 3;8(35):57991-58002. doi: 10.18632/oncotarget.19854. eCollection 2017 Aug 29.

8.

The anti-vascular endothelial growth factor receptor-1 monoclonal antibody D16F7 inhibits invasiveness of human glioblastoma and glioblastoma stem cells.

Atzori MG, Tentori L, Ruffini F, Ceci C, Lisi L, Bonanno E, Scimeca M, Eskilsson E, Daubon T, Miletic H, Ricci Vitiani L, Pallini R, Navarra P, Bjerkvig R, D'Atri S, Lacal PM, Graziani G.

J Exp Clin Cancer Res. 2017 Aug 10;36(1):106. doi: 10.1186/s13046-017-0577-2.

9.

Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth.

Ceci C, Tentori L, Atzori MG, Lacal PM, Bonanno E, Scimeca M, Cicconi R, Mattei M, de Martino MG, Vespasiani G, Miano R, Graziani G.

Nutrients. 2016 Nov 22;8(11). pii: E744.

10.

Antitumor activity of a novel anti-vascular endothelial growth factor receptor-1 monoclonal antibody that does not interfere with ligand binding.

Graziani G, Ruffini F, Tentori L, Scimeca M, Dorio AS, Atzori MG, Failla CM, Morea V, Bonanno E, D'Atri S, Lacal PM.

Oncotarget. 2016 Nov 8;7(45):72868-72885. doi: 10.18632/oncotarget.12108.

11.

Exploiting Microglial Functions for the Treatment of Glioblastoma.

Dello Russo C, Lisi L, Tentori L, Navarra P, Graziani G, Combs CK.

Curr Cancer Drug Targets. 2017;17(3):267-281. doi: 10.2174/1568009616666160813191240. Review.

PMID:
27528361
12.

A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.

Biochem Pharmacol. 2015 May 1;95(1):16-27. doi: 10.1016/j.bcp.2015.03.004. Epub 2015 Mar 17.

PMID:
25795251
13.

Cilengitide downmodulates invasiveness and vasculogenic mimicry of neuropilin 1 expressing melanoma cells through the inhibition of αvβ5 integrin.

Ruffini F, Graziani G, Levati L, Tentori L, D'Atri S, Lacal PM.

Int J Cancer. 2015 Mar 15;136(6):E545-58. doi: 10.1002/ijc.29252. Epub 2014 Nov 28.

14.

Mutations of human DNA topoisomerase I at poly(ADP-ribose) binding sites: modulation of camptothecin activity by ADP-ribose polymers.

Tesauro C, Graziani G, Arnò B, Zuccaro L, Muzi A, D'Annessa I, Santori E, Tentori L, Leonetti C, Fiorani P, Desideri A.

J Exp Clin Cancer Res. 2014 Sep 17;33:71. doi: 10.1186/s13046-014-0071-z.

15.

Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.

Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P, Graziani G.

BMC Cancer. 2014 Mar 5;14:151. doi: 10.1186/1471-2407-14-151.

16.

PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.

Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G.

Front Oncol. 2013 Nov 14;3:279. doi: 10.3389/fonc.2013.00279. eCollection 2013. Review. No abstract available.

17.

Challenging resistance mechanisms to therapies for metastatic melanoma.

Tentori L, Lacal PM, Graziani G.

Trends Pharmacol Sci. 2013 Dec;34(12):656-66. doi: 10.1016/j.tips.2013.10.003. Epub 2013 Nov 7. Review.

PMID:
24210882
18.

Platelet-derived growth factor C and calpain-3 are modulators of human melanoma cell invasiveness.

Ruffini F, Tentori L, Dorio AS, Arcelli D, D'Amati G, D'Atri S, Graziani G, Lacal PM.

Oncol Rep. 2013 Dec;30(6):2887-96. doi: 10.3892/or.2013.2791. Epub 2013 Oct 10.

PMID:
24126726
19.

Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.

Tentori L, Leonetti C, Muzi A, Dorio AS, Porru M, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.

Int J Oncol. 2013 Jul;43(1):210-8. doi: 10.3892/ijo.2013.1932. Epub 2013 May 8.

PMID:
23653048
20.

MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.

Tentori L, Muzi A, Dorio AS, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G.

Cancer Chemother Pharmacol. 2013 Jul;72(1):117-25. doi: 10.1007/s00280-013-2175-0. Epub 2013 May 1.

PMID:
23636450
21.

Targeted therapy for brain tumours: role of PARP inhibitors.

Leonetti C, Biroccio A, Graziani G, Tentori L.

Curr Cancer Drug Targets. 2012 Mar;12(3):218-36. Review.

PMID:
22268386
22.

Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.

Graziani G, Tentori L, Navarra P.

Pharmacol Res. 2012 Jan;65(1):9-22. doi: 10.1016/j.phrs.2011.09.002. Epub 2011 Sep 10. Review.

PMID:
21930211
23.

Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1.

Vernole P, Muzi A, Volpi A, Terrinoni A, Dorio AS, Tentori L, Shah GM, Graziani G.

Mutat Res. 2011 Jul 1;712(1-2):40-8. doi: 10.1016/j.mrfmmm.2011.03.006. Epub 2011 May 5.

PMID:
21570414
24.

The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.

Tentori L, Dorio AS, Mazzon E, Muzi A, Sau A, Cuzzocrea S, Vernole P, Federici G, Caccuri AM, Graziani G.

Eur J Cancer. 2011 May;47(8):1219-30. doi: 10.1016/j.ejca.2010.12.008. Epub 2011 Jan 25.

PMID:
21269821
25.

PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.

Salvati E, Scarsella M, Porru M, Rizzo A, Iachettini S, Tentori L, Graziani G, D'Incalci M, Stevens MF, Orlandi A, Passeri D, Gilson E, Zupi G, Leonetti C, Biroccio A.

Oncogene. 2010 Nov 25;29(47):6280-93. doi: 10.1038/onc.2010.344. Epub 2010 Aug 30.

PMID:
20802516
26.

Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.

Tentori L, Muzi A, Dorio AS, Scarsella M, Leonetti C, Shah GM, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J, Graziani G.

Curr Cancer Drug Targets. 2010 Jun;10(4):368-83.

PMID:
20464779
27.

Evidence of the crucial role of the linker domain on the catalytic activity of human topoisomerase I by experimental and simulative characterization of the Lys681Ala mutant.

Fiorani P, Tesauro C, Mancini G, Chillemi G, D'Annessa I, Graziani G, Tentori L, Muzi A, Desideri A.

Nucleic Acids Res. 2009 Nov;37(20):6849-58. doi: 10.1093/nar/gkp669. Epub 2009 Sep 18.

28.

Pharmacological inhibition of poly(ADP-ribose) polymerase activity down-regulates the expression of syndecan-4 and Id-1 in endothelial cells.

Lacal PM, Tentori L, Muzi A, Ruffini F, Dorio AS, Xu W, Arcelli D, Zhang J, Graziani G.

Int J Oncol. 2009 Mar;34(3):861-72.

PMID:
19212692
29.

Recent approaches to improve the antitumor efficacy of temozolomide.

Tentori L, Graziani G.

Curr Med Chem. 2009;16(2):245-57. Review.

PMID:
19149575
30.

Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.

Lacal PM, Morea V, Ruffini F, Orecchia A, Dorio AS, Failla CM, Soro S, Tentori L, Zambruno G, Graziani G, Tramontano A, D'Atri S.

Eur J Cancer. 2008 Sep;44(13):1914-21. doi: 10.1016/j.ejca.2008.06.032. Epub 2008 Aug 3.

PMID:
18682321
31.

Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity.

Tentori L, Muzi A, Dorio AS, Bultrini S, Mazzon E, Lacal PM, Shah GM, Zhang J, Navarra P, Nocentini G, Cuzzocrea S, Graziani G.

Eur J Cancer. 2008 Jun;44(9):1302-14. doi: 10.1016/j.ejca.2008.03.019. Epub 2008 Apr 24.

PMID:
18440222
32.

The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.

Tentori L, Dorio AS, Muzi A, Lacal PM, Ruffini F, Navarra P, Graziani G.

Oncol Rep. 2008 Apr;19(4):1039-43.

PMID:
18357394
33.

Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.

Tentori L, Lacal PM, Muzi A, Dorio AS, Leonetti C, Scarsella M, Ruffini F, Xu W, Min W, Stoppacciaro A, Colarossi C, Wang ZQ, Zhang J, Graziani G.

Eur J Cancer. 2007 Sep;43(14):2124-33. Epub 2007 Aug 21.

PMID:
17714938
34.

Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?

Tentori L, Graziani G.

Pharmacol Res. 2007 May;55(5):359-69. Epub 2007 Feb 3. Review.

PMID:
17349798
35.

Evidence that corticotropin-releasing hormone inhibits cell growth of human breast cancer cells via the activation of CRH-R1 receptor subtype.

Graziani G, Tentori L, Muzi A, Vergati M, Tringali G, Pozzoli G, Navarra P.

Mol Cell Endocrinol. 2007 Jan 29;264(1-2):44-9. Epub 2006 Nov 9.

PMID:
17097220
36.

Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.

Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, Forini O, Lapidus R, Xu W, Dorio AS, Zhang J, Cuzzocrea S, Graziani G.

FASEB J. 2006 Aug;20(10):1709-11. Epub 2006 Jun 29.

PMID:
16809434
37.

Corticotropin-releasing hormone receptor-1 in human endometrial cancer.

Graziani G, Ferrandina G, Pozzoli G, Vergati M, Muzi A, Legge F, Tentori L, Scambia G, Navarra P.

Oncol Rep. 2006 Feb;15(2):375-9.

PMID:
16391857
38.

Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.

Tentori L, Leonetti C, Scarsella M, Muzi A, Vergati M, Forini O, Lacal PM, Ruffini F, Gold B, Li W, Zhang J, Graziani G.

Eur J Cancer. 2005 Dec;41(18):2948-57. Epub 2005 Nov 8.

PMID:
16288862
39.

Role of the mismatch repair system and p53 in the clastogenicity and cytotoxicity induced by bleomycin.

Vernole P, Tedeschi B, Tentori L, Levati L, Argentin G, Cicchetti R, Forini O, Graziani G, D'Atri S.

Mutat Res. 2006 Feb 22;594(1-2):63-77. Epub 2005 Sep 1.

PMID:
16139849
40.

Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs.

Tentori L, Vergati M, Muzi A, Levati L, Ruffini F, Forini O, Vernole P, Lacal PM, Graziani G.

Int J Oncol. 2005 Aug;27(2):525-35.

PMID:
16010436
41.

Chemopotentiation by PARP inhibitors in cancer therapy.

Tentori L, Graziani G.

Pharmacol Res. 2005 Jul;52(1):25-33. Review.

PMID:
15911331
42.

Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.

Tentori L, Leonetti C, Scarsella M, Vergati M, Xu W, Calvin D, Morgan L, Tang Z, Woznizk K, Alemu C, Hoover R, Lapidus R, Zhang J, Graziani G.

Int J Oncol. 2005 Feb;26(2):415-22.

PMID:
15645126
43.

N3-methyladenine induces early poly(ADP-ribosylation), reduction of nuclear factor-kappa B DNA binding ability, and nuclear up-regulation of telomerase activity.

Tentori L, Forini O, Fossile E, Muzi A, Vergati M, Portarena I, Amici C, Gold B, Graziani G.

Mol Pharmacol. 2005 Feb;67(2):572-81. Epub 2004 Nov 17.

PMID:
15548765
45.

Primary cultures of microglial cells for testing toxicity of anticancer drugs.

Vairano M, Graziani G, Tentori L, Tringali G, Navarra P, Dello Russo C.

Toxicol Lett. 2004 Mar 14;148(1-2):91-4.

PMID:
15019092
46.

Residual telomerase activity: a marker of cell survival after exposure to gamma radiation in vitro.

Turriziani M, Di Giacomo AM, Cardillo A, Torino F, Tentori L, Nasuti P, Massara MC, Roselli M, Bonmassar E, De Vecchis L.

Anticancer Res. 2003 Nov-Dec;23(6C):4561-9.

PMID:
14981897
47.

Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.

Tentori L, Leonetti C, Scarsella M, D'Amati G, Vergati M, Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G.

Clin Cancer Res. 2003 Nov 1;9(14):5370-9.

48.

Valproic acid increases the stimulatory effect of estrogens on proliferation of human endometrial adenocarcinoma cells.

Graziani G, Tentori L, Portarena I, Vergati M, Navarra P.

Endocrinology. 2003 Jul;144(7):2822-8.

PMID:
12810536
49.

Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.

Tentori L, Portarena I, Barbarino M, Balduzzi A, Levati L, Vergati M, Biroccio A, Gold B, Lombardi ML, Graziani G.

Mol Pharmacol. 2003 Jan;63(1):192-202.

PMID:
12488552
50.

Supplemental Content

Loading ...
Support Center